Welcome to our dedicated page for Vicarious Surgical SEC filings (Ticker: RBOT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vicarious Surgical Inc. filings document the company's robotic surgery business, capital structure, governance actions, and public-market status. Recent 8-K reports cover operating results, financial condition, executive employment agreement amendments, and NYSE delisting proceedings for the company's Class A common stock, which is quoted on the OTC market under RBOT.
Proxy and shareholder-vote filings describe amendments to the certificate of incorporation related to a reverse stock split authorization and the voting mechanics of the company's Class A and Class B common stock. Form 25 and related reports document removal of the Class A common stock from NYSE listing and registration under Section 12(b).
Vicarious Surgical, Inc. approved a general assignment for the benefit of creditors, transferring all or substantially all assets to Vicarious Liquidation, LLC. Under this structure, creditors are expected to have priority over stockholders for distributions, and stockholders are not expected to receive any distribution unless assets remain after satisfying all liabilities.
Stockholders at a Special Meeting approved an assignment for the benefit of creditors followed by a voluntary dissolution and liquidation. The board then determined the dissolution was in the company’s best interests and approved a Plan of Dissolution, under which a Certificate of Dissolution will be filed with the Delaware Secretary of State on or about July 22, 2026.
The board decided to voluntarily terminate registration of the common stock and intends to file Form 15, which will immediately suspend obligations to file Forms 10-K, 10-Q and 8-K and is expected to become effective 90 days after filing. All directors have submitted resignations effective upon the Form 15 filing, and the CEO, President, CTO and Chief Medical Officer were terminated on July 21, 2026, with contractual cash severance of $672,699, $779,190 and $611,261 respectively and full vesting of their time-based equity awards, subject to treatment under the assignment and applicable law.
Vicarious Surgical Inc. reported that Chief Financial Officer Sarah Romano has resigned. She notified the Board on June 24, 2026, with her resignation effective July 22, 2026, or a later mutually agreed date. The company states her resignation is not due to any disagreement regarding operations, policies, or practices. Ms. Romano will continue to serve as CFO until her resignation becomes effective.
Vicarious Surgical Inc. is asking stockholders to approve an assignment for the benefit of creditors followed by a complete dissolution under a Plan of Dissolution. The company states that, based on its current liabilities, it is unlikely common stockholders will receive any cash distribution.
As of March 31, 2026, Vicarious Surgical reported total assets of $12.586 million, total liabilities of $9.016 million, and cash, cash equivalents and short-term investments of $3.682 million, which it does not expect to support it as a going concern for long. The board reports unsuccessful efforts to secure additional financing or a buyer and believes an assignment for the benefit of creditors plus dissolution offers a better recovery path for creditors than bankruptcy, with only a remote chance of residual value for equity holders.